Capstone Investment Advisors
ONC

Capstone Investment Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Capstone Investment Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,000
Closed -$377K – 2164
2022
Q1 		$377K Buy
+2,000
New +$425K ﹤0.01% 1550

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capstone Investment Advisors's ONC Position: Q1 2025 in Review

Capstone Investment Advisors sold out of BeOne Medicines Ltd (ONC) in Q1 2025, closing a stake of 2,967 shares — an estimated $548K sold.

Capstone Investment Advisors first reported a position in ONC in Q3 2024 and held it in 2 quarters. The position peaked at $1.19M in Q3 2024. 267 funds tracked by Wall St. Rank hold ONC as of Q1 2025.

  • Capstone Investment Advisors reported no remaining BeOne Medicines Ltd position as of Q1 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,967 BeOne Medicines Ltd shares in Q1 2025, an estimated $548K.
  • Capstone Investment Advisors first reported a position in BeOne Medicines Ltd in Q3 2024 and held it in 2 quarters.
  • Capstone Investment Advisors's BeOne Medicines Ltd position peaked at $1.19M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2025.

Based on Capstone Investment Advisors's 13F filing for Q1 2025, filed 15 May 2025.